LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

HomeStock ListCerevel Therapeutics Holdings Inc

Cerevel Therapeutics Holdings Inc

Closed

42.13 0.02

Overview

Share price change

24h

Current

Min

41.86

Max

42.19

Recommendations

By TipRanks

Rating Consensus

Neutral

12 Months Forecast

+6.71 upside

Dividends

By Dow Jones

Next earnings

1 May 2024

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Cerevel Therapeutics Holdings Inc chart

Related News

22 Dec 2023, 16:00 UTC

Acquisitions, Mergers, TakeOvers

Trending: Bristol Myers to Buy Karuna Therapeutics for $14 Billion

7 Dec 2023, 15:12 UTC

Acquisitions, Mergers, TakeOvers

Trending: AbbVie to Buy Cerevel for $45 a Share

6 Dec 2023, 21:55 UTC

Acquisitions, Mergers, TakeOvers

AbbVie to Buy Cerevel Therapeutics for $8.7 Billion -- Update

6 Dec 2023, 21:50 UTC

Acquisitions, Mergers, TakeOvers

AbbVie to Buy Cerevel Therapeutics for $8.7 Billion

6 Dec 2023, 21:44 UTC

Acquisitions, Mergers, TakeOvers

AbbVie Close to $8 Billion Deal for Cerevel Therapeutics, Sources Say, Reuters Reports

12 Feb 2024, 12:51 UTC

Acquisitions, Mergers, TakeOvers

AbbVie's Stock Dips Premarket After It Lowers Q1 Guidance To Reflect Dilutive Impact Of ImmunoGen Deal Close -- MarketWatch

8 Dec 2023, 16:14 UTC

Acquisitions, Mergers, TakeOvers

Biotech Deals Are Heating Up. Why 2024 Could Be Even Hotter for M&A. -- Barrons.com

8 Dec 2023, 12:00 UTC

Top News
Earnings
Acquisitions, Mergers, TakeOvers

19 Billion in a Week: AbbVie Makes Two Big Bets -- Heard on the Street -- WSJ

7 Dec 2023, 18:34 UTC

Market Talk
Acquisitions, Mergers, TakeOvers

Neuro-Drug Makers Looking Valuable After AbbVie-Cerevel Deal -- Market Talk

7 Dec 2023, 18:05 UTC

Market Talk
Acquisitions, Mergers, TakeOvers

AbbVie-Cerevel Deal Could Get Regulatory Scrutiny -- Market Talk

7 Dec 2023, 13:23 UTC

Market Talk
Acquisitions, Mergers, TakeOvers

AbbVie Betting on Cerevel Schizophrenia Candidate -- Market Talk

7 Dec 2023, 12:48 UTC

Market Talk
Acquisitions, Mergers, TakeOvers

AbbVie Dividend Secure Despite Deal-Making -- Market Talk

7 Dec 2023, 10:33 UTC

Acquisitions, Mergers, TakeOvers

AbbVie Makes Another Big Pharma Acquisition. How It's Putting Its Cash to Work. -- Barrons.com

6 Dec 2023, 21:32 UTC

Acquisitions, Mergers, TakeOvers

AbbVie: Emraclidine Has Potential to Transform the Standard of Care in Schizophrenia and Other Psychiatric Conditions >ABBV

6 Dec 2023, 21:32 UTC

Acquisitions, Mergers, TakeOvers

AbbVie: Cerevel's Clinical-Stage Pipeline Complements AbbVie's Current on-Market Portfolio and Emerging Neuroscience Pipeline >ABBV

6 Dec 2023, 21:32 UTC

Acquisitions, Mergers, TakeOvers

AbbVie: Transaction Valued at $45.00 Per Shr in Cash, for a Total Equity Value of Approximately $8.7B >ABBV

6 Dec 2023, 21:32 UTC

Acquisitions, Mergers, TakeOvers

AbbVie: Proposed Acquisition Adds Pipeline Focused on Best-in-Class Potential for Psychiatric and Neurological Disorders Where Significant Unmet Needs Remain >ABBV

6 Dec 2023, 21:30 UTC

Acquisitions, Mergers, TakeOvers

AbbVie To Acquire Cerevel Therapeutics In Transformative Transaction To Strengthen Neuroscience Pipeline >ABBV CERE

6 Dec 2023, 21:29 UTC

Acquisitions, Mergers, TakeOvers

AbbVie Close to $8B Deal for Cerevel Therapeutics, Sources Say, Reuters Reports

Peer Comparison

Price change

Cerevel Therapeutics Holdings Inc forecast

Price Target

By TipRanks

6.71% upside

12 Months Forecast

Average 45 USD  6.71%

High 45 USD

Low 45 USD

Based on 2 Wall Street analysts offering 12 month price targets for Cerevel Therapeutics Holdings Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

2 ratings

0

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

42.195 / 42.4 Support&Resistance

Short Team

Strong Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bullish Evidence